Skip to main content

Table 2 Comparison of different patient groups according to their genotype respect to PFS and drug response

From: SMAD4 and NF1 mutations as potential biomarkers for poor prognosis to cetuximab-based therapy in Chinese metastatic colorectal cancer patients

  Number of patients
(n=)
Median PFS
(days)
Total patients 33 211
SMAD4 mut 8 90
SMAD4 wt 25 250
NF1 mut 4 53.5
NF1 wt 29 211
SMAD4mut or NF1mut 10 90
SMAD4wt and NF1wt 23 250
KRAS mut 9 99
KRAS wt 24 230.5